These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

60 related items for PubMed ID: 1978370

  • 1. Gepirone as a 5-HT1A agonist in the treatment of major depression.
    Rausch JL, Ruegg R, Moeller FG.
    Psychopharmacol Bull; 1990; 26(2):169-71. PubMed ID: 1978370
    [Abstract] [Full Text] [Related]

  • 2. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE, Franznick DA, Hollander SB, Fava M.
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [Abstract] [Full Text] [Related]

  • 3. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.
    Feiger AD, Heiser JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JM, Gibertini M.
    J Clin Psychiatry; 2003 Mar; 64(3):243-9. PubMed ID: 12716264
    [Abstract] [Full Text] [Related]

  • 4. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression.
    Feiger AD.
    Psychopharmacol Bull; 1996 Mar; 32(4):659-65. PubMed ID: 8993088
    [Abstract] [Full Text] [Related]

  • 5. Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement.
    McGrath PJ, Stewart JW, Quitkin FM, Wager S, Jenkins SW, Archibald DG, Stringfellow JC, Robinson DS.
    J Clin Psychopharmacol; 1994 Oct; 14(5):347-52. PubMed ID: 7806692
    [Abstract] [Full Text] [Related]

  • 6. Ipsapirone: evidence for efficacy in depression.
    Heller AH, Beneke M, Kuemmel B, Spencer D, Kurtz NM.
    Psychopharmacol Bull; 1990 Oct; 26(2):219-22. PubMed ID: 1978372
    [Abstract] [Full Text] [Related]

  • 7. Buspirone in the management of major depression: a placebo-controlled comparison.
    Fabre LF.
    J Clin Psychiatry; 1990 Sep; 51 Suppl():55-61. PubMed ID: 2211570
    [Abstract] [Full Text] [Related]

  • 8. Gepirone, a selective serotonin (5HT1A) partial agonist in the treatment of major depression.
    Amsterdam JD.
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 May; 16(3):271-80. PubMed ID: 1350353
    [Abstract] [Full Text] [Related]

  • 9. Open trial of buspirone in the treatment of major depressive disorder.
    Schweizer EE, Amsterdam J, Rickels K, Kaplan M, Droba M.
    Psychopharmacol Bull; 1986 May; 22(1):183-5. PubMed ID: 2873610
    [No Abstract] [Full Text] [Related]

  • 10. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.
    Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, Murphy JH, Haq N, Rubinow DR.
    Arch Gen Psychiatry; 2005 Feb; 62(2):154-62. PubMed ID: 15699292
    [Abstract] [Full Text] [Related]

  • 11. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients.
    Wilcox CS, Ferguson JM, Dale JL, Heiser JF.
    Psychopharmacol Bull; 1996 Feb; 32(3):335-42. PubMed ID: 8961776
    [Abstract] [Full Text] [Related]

  • 12. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
    Fawcett J, Barkin RL.
    J Clin Psychiatry; 1998 Mar; 59(3):123-7. PubMed ID: 9541155
    [Abstract] [Full Text] [Related]

  • 13. Gepirone in the treatment of major depression.
    Jenkins SW, Robinson DS, Fabre LF, Andary JJ, Messina ME, Reich LA.
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):77S-85S. PubMed ID: 1973942
    [Abstract] [Full Text] [Related]

  • 14. Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
    Fawcett J, Marcus RN, Anton SF, O'Brien K, Schwiderski U.
    J Clin Psychiatry; 1995 Jun; 56 Suppl 6():37-42. PubMed ID: 7649972
    [Abstract] [Full Text] [Related]

  • 15. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression.
    Robinson DS, Rickels K, Feighner J, Fabre LF, Gammans RE, Shrotriya RC, Alms DR, Andary JJ, Messina ME.
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):67S-76S. PubMed ID: 2198303
    [Abstract] [Full Text] [Related]

  • 16. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression.
    Malhi GS, Ng F, Berk M.
    Aust N Z J Psychiatry; 2008 Apr; 42(4):346-9. PubMed ID: 18330778
    [Abstract] [Full Text] [Related]

  • 17. Cortisol and growth hormone responses to the 5-HT1A agonist gepirone in depressed patients.
    Rausch JL, Stahl SM, Hauger RL.
    Biol Psychiatry; 1990 Jul 01; 28(1):73-8. PubMed ID: 1973905
    [Abstract] [Full Text] [Related]

  • 18. Buspirone in depressed outpatients: a controlled study.
    Rickels K, Amsterdam J, Clary C, Hassman J, London J, Puzzuoli G, Schweizer E.
    Psychopharmacol Bull; 1990 Jul 01; 26(2):163-7. PubMed ID: 2236452
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study.
    Lee ST, Park JH, Kim M.
    Headache; 2005 Sep 01; 45(8):1004-11. PubMed ID: 16109114
    [Abstract] [Full Text] [Related]

  • 20. Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial.
    Amsterdam JD, Brunswick DJ, Gibertini M.
    J Psychiatr Res; 2004 Sep 01; 38(3):259-65. PubMed ID: 15003431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.